Leslie D. Funtleyder - Dec 19, 2024 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)

Role: Interim Chief Executive Officer and Chief Financial Officer, Director
Signature: /s/ Leslie D. Funtleyder
Stock symbol: APLT
Transactions as of: Dec 19, 2024
Transactions value $: $0
Form type: 4
Date filed: 12/20/2024, 08:30 PM
Previous filing: Dec 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLT	Common Stock	Award	$0	+150K	+53.97%	$0.00	428K	Dec 19, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLT	Stock Option (Right to Buy)	Award	$0	+150K		$0.00	150K	Dec 19, 2024	Common Stock	150K	$1.02	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of compensatory Restricted Stock Units ("RSUs") granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan") in connection with the Reporting Person's service as interim Chief Executive Officer. Each compensatory RSU represents a contingent right to receive one share of the issuer's common stock. The compensatory RSUs will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested RSUs will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).
F2	Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

Content

Consists of compensatory Restricted Stock Units ("RSUs") granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan") in connection with the Reporting Person's service as interim Chief Executive Officer. Each compensatory RSU represents a contingent right to receive one share of the issuer's common stock. The compensatory RSUs will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested RSUs will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

Remarks:

Interim Chief Executive Officer and Chief Financial Officer